Page last updated: 2024-12-06

5-nitro-1,10-phenanthroline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Nitro-1,10-phenanthroline is a heterocyclic compound that is used as a chelating agent in the synthesis of coordination complexes with transition metals. It is synthesized by the nitration of 1,10-phenanthroline. This compound has been studied for its potential applications in various fields, including catalysis, luminescence, and biological activity. For example, complexes of 5-nitro-1,10-phenanthroline with ruthenium(II) have been found to be highly efficient catalysts for the oxidation of alcohols. Additionally, the compound exhibits photoluminescent properties and can be used in the development of new light-emitting materials. Furthermore, 5-nitro-1,10-phenanthroline has shown antimicrobial activity against a variety of bacteria and fungi, suggesting potential applications in the development of new antibiotics. The compound's unique electronic properties and its ability to coordinate with various metal ions make it a valuable building block for the synthesis of functional materials.'

5-nitro-1,10-phenanthroline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72790
CHEMBL ID101815
SCHEMBL ID670669
MeSH IDM0515876

Synonyms (37)

Synonym
CHEMBL101815
5-nitro-[1,10]phenanthroline
5-nitro-1,10-phenanthroline
nsc4263
mls000736506 ,
5-nitro-1, 10-diazaphenanthrene
4199-88-6
nsc-4263
5-nitro-1,10-phenanthroline, >=97%, crystalline
smr000445932
pddbtwxlnjnics-uhfffaoysa-
inchi=1/c12h7n3o2/c16-15(17)10-7-8-3-1-5-13-11(8)12-9(10)4-2-6-14-12/h1-7h
AKOS003368622
N0214
NCGC00246911-01
A825712
nsc 4263
1,10-phenanthroline, 5-nitro-
einecs 224-097-6
HMS2784C21
FT-0620678
SCHEMBL670669
5nitro-1, 10-phenanthroline
DTXSID7063346
5-nitro-1,10-diazaphenanthrene
J-400717
c12h7n3o2
mfcd00004981
GS-5654
CS-W004570
SY039159
10.14272/PDDBTWXLNJNICS-UHFFFAOYSA-N.1
doi:10.14272/pddbtwxlnjnics-uhfffaoysa-n.1
AMY23551
5-np
PD158530
HY-W004570
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency22.33420.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency7.94330.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency7.30480.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency17.35820.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency31.62280.180013.557439.8107AID1460
Smad3Homo sapiens (human)Potency11.22020.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.54810.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency22.38720.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency16.36010.005210.865235.4813AID686970
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency19.95260.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency14.58100.004611.374133.4983AID624297
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency35.48130.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID158223In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10; Not determined2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
In vitro antimalarial activity of a series of cationic 2,2'-bipyridyl- and 1,10-phenanthrolineplatinum(II) benzoylthiourea complexes.
AID1883770Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth incubated for 14 days2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID1883857Cytotoxicity against human THP-1 cells assessed as reduction in cell viability treated for 96 hrs by MTT assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID72977Ability to associate with ferriprotoporphyrin IX2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
In vitro antimalarial activity of a series of cationic 2,2'-bipyridyl- and 1,10-phenanthrolineplatinum(II) benzoylthiourea complexes.
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID218537Inhibition of beta-hematin formation; Not active2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
In vitro antimalarial activity of a series of cationic 2,2'-bipyridyl- and 1,10-phenanthrolineplatinum(II) benzoylthiourea complexes.
AID158225In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum K1; Not determined2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
In vitro antimalarial activity of a series of cationic 2,2'-bipyridyl- and 1,10-phenanthrolineplatinum(II) benzoylthiourea complexes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's1 (8.33)18.2507
2000's3 (25.00)29.6817
2010's5 (41.67)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.71 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]